aluxum William Blair downgraded BioMarin Pharmaceutical ( NASDAQ: BMRN ) to market perform from outperform following the company's Q3 financial results when the biotech narrowed its 2024 revenue guidance. The company now sees full-year revenue $2.79B to $2.
825B compared to $2.75B to $2.825B prior.
Consensus is $2.81B..
